Related Experiment Video
Updated: Jul 4, 2026
08:54
Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
Predictors of Relapse in Oligometastatic Prostate Patients Receiving Stereotactic Ablative Radiotherapy.
Saleh Sandoughdaran1, Veni Ezhil1, Christos Mikropoulos1
1Royal Surrey County Hospital, Guildford, UK.
The British Journal of Radiology
|July 3, 2026
Summary
Prostate cancer patients undergoing Stereotactic Ablative Radiotherapy (SABR) relapse risk is best predicted by PSA levels after treatment, not traditional markers. Early PSA reduction post-SABR indicates a significantly lower chance of recurrence.
Area of Science:
- Oncology
- Radiation Oncology
- Prostate Cancer Research
Background:
- Oligometastatic prostate cancer presents a treatment challenge, with limited understanding of relapse predictors post-SABR.
- Conventional prognostic factors may not adequately stratify relapse risk in this specific patient group.
Purpose of the Study:
- To identify predictors of disease relapse in patients with oligometastatic prostate cancer treated with Stereotactic Ablative Radiotherapy (SABR).
- To evaluate the efficacy of PSA kinetics as a prognostic biomarker compared to traditional factors.
Main Methods:
- Retrospective analysis of 57 oligometastatic prostate cancer patients treated with SABR (30 Gy in 3-5 fractions).
- Kaplan-Meier and Cox regression analyses were employed to identify prognostic factors for disease-free survival (DFS).
- Primary endpoint: DFS; Secondary endpoints: local relapse rates.
Main Results:
- Median follow-up was 34.5 months; 1-year and 2-year DFS rates were 64.5% and 24.3%.
- Local control was achieved in 87% of patients.
- Post-SABR PSA reduction was the sole significant predictor of relapse (HR=0.235, p=0.005), indicating a 76.5% lower recurrence risk. Traditional markers showed no significant correlation.
Conclusions:
- Post-SABR PSA kinetics are a more reliable predictor of relapse than conventional risk factors in oligometastatic prostate cancer.
- Early PSA reduction post-SABR is independently associated with reduced relapse risk, suggesting its utility in guiding follow-up intensity and identifying high-risk patients.
